Correlation between Serum Uric Acid Level and Left Ventricular Ejection Fraction in Patients with Heart Failure
Related Experiment Video
Updated: Jan 8, 2026

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
Published on: February 20, 2017
Manvi Sakhuja1, Manish Pendse2, Smita Patil3
1Senior Resident, Department of Internal Medicine, Sir Ganga Ram Hospital, Delhi, India, Orcid: https://orcid.org/0009-0009-0987-2810, Corresponding Author.
Insights
Serum uric acid (SUA) levels do not reliably predict heart failure severity. This study found no significant correlation between SUA and left ventricular ejection fraction (LVEF) in heart failure patients.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Research
Background:
- Heart failure (HF) is a growing global health issue.
- Serum uric acid (SUA) is being investigated as a potential biomarker for HF severity.
- The link between SUA and left ventricular ejection fraction (LVEF) in HF requires further clarification.
Purpose of the Study:
- To investigate the correlation between serum uric acid (SUA) levels and left ventricular ejection fraction (LVEF) in patients with heart failure.
- To determine if SUA can serve as a biomarker for the severity of systolic dysfunction in HF.
Main Methods:
- A cross-sectional study included 60 heart failure patients.
- Patients were classified by LVEF: HFpEF, HFmrEF, and HFrEF.
- Serum uric acid (SUA) levels were measured and correlated with LVEF and HF classification.
Main Results:
- A weak, statistically insignificant negative correlation (r = -0.070, p = 0.599) was observed between LVEF and SUA.
- Hyperuricemia was more common in patients with reduced ejection fraction (HFrEF).
- No significant relationship was found between SUA levels and the severity of systolic dysfunction.
Conclusions:
- Serum uric acid (SUA) is not a reliable biomarker for assessing systolic dysfunction severity in heart failure patients.
- The current findings suggest SUA's prognostic role in HF remains uncertain.
- Larger, diverse studies are recommended to further explore SUA's role in heart failure.
Background:
Heart failure (HF) is a major public health concern with increasing prevalence worldwide. Serum uric acid (SUA) has been proposed as a potential biomarker in HF, with its levels potentially correlating with the severity of systolic dysfunction. However, the relationship between SUA and left ventricular ejection fraction (LVEF) remains unclear.
Methodology:
A cross-sectional study was conducted at DY Patil University School of Medicine, Navi Mumbai, involving 60 patients diagnosed with HF. Patients were categorized based on LVEF into HF with preserved ejection fraction (HFpEF), mid-range ejection fraction (HFmrEF), and reduced ejection fraction (HFrEF). SUA levels were measured, and patients were classified into hyperuricemia or normal uric acid level groups. Demographics, comorbidities, and clinical symptoms were also recorded. Statistical analysis was performed to determine the correlation between SUA and LVEF.
Results:
Of the 60 patients enrolled, 65% were female, with a mean age of 61-70 years. The majority had HFrEF (70%), followed by HFmrEF (26.67%) and HFpEF (3.3%). Hyperuricemia was observed in 38.3% of patients. A weak negative correlation was found between LVEF and SUA (r = -0.070), which was not statistically significant (p = 0.599). Although hyperuricemia was more prevalent in HFrEF, no significant relationship was established between SUA levels and severity of systolic dysfunction.
Conclusion:
The study found a weak and statistically insignificant correlation between SUA levels and LVEF in HF patients. This suggests that SUA may not be a reliable biomarker for assessing the severity of systolic dysfunction. Further studies involving larger, more diverse populations are needed to clarify the prognostic role of SUA in HF.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Pathophysiology of Heart Failure
Heart Failure V: Medical Management
Heart Failure III: Clinical Manifestations
Heart Failure II: Pathophysiology
Heart Failure IV: Classification and Diagnostic Evaluation

